What is the recommended management for hemolytic anemia?

Management of Hemolytic Anemia

For warm autoimmune hemolytic anemia (wAIHA), initiate corticosteroids as first-line therapy, with rituximab as the preferred second-line agent for relapsed or refractory cases; for cold agglutinin disease (CAD), use rituximab with or without bendamustine as first-line therapy. 1, 2

Initial Diagnostic Classification

Before initiating treatment, classify the hemolytic anemia using the direct antiglobulin test (DAT) as the cornerstone diagnostic tool 2, 3:

• DAT-positive (immune-mediated): Proceed with antibody characterization to distinguish warm vs. cold antibodies
• DAT-negative (non-immune): Consider hemoglobinopathies, microangiopathic processes, or other non-immune causes 4

Perform monospecific DAT to identify the specific antibody type, as this directly determines treatment strategy 2. Exclude secondary causes in all cases (lymphoproliferative disorders, infections, autoimmune diseases, drugs including checkpoint inhibitors, hematopoietic stem cell transplantation) 1, 3.

Emergency and Supportive Measures (All Types)

Regardless of etiology, implement these measures immediately for clinically significant hemolysis 1, 4:

• Blood transfusions when anemia is symptomatic or life-threatening
• Prophylactic anticoagulation for severe hemolysis (high thromboembolism risk)
• Recombinant erythropoietin when reticulocytopenia or inadequate bone marrow compensation is present
• Monitor for complications: pigment gallstones, high-output cardiac failure, thromboembolism

Warm Autoimmune Hemolytic Anemia (wAIHA) - 60-70% of Cases

First-Line Treatment

Corticosteroids remain the standard first-line therapy 1, 2, 3:

• Prednisone 1-4 mg/kg/day
• Continue for 2-4 weeks, then slow taper after hemoglobin normalizes 5

Add rituximab early in the following scenarios 1:

• Severe cases at presentation
• No prompt response to steroids
• Life-threatening hemolysis

Second-Line Treatment

Rituximab is now the preferred second-line option, comparing favorably with traditional splenectomy 1, 6:

• Dose: 375 mg/m² weekly for 4 weeks, or repeated after 2 weeks 7
• Rituximab plays a central role in both wAIHA and CAD management 6

Third-Line and Beyond

Reserve these for later lines 1:

• Splenectomy (increasingly reserved due to rituximab efficacy)
• Classic immunosuppressants (azathioprine, cyclophosphamide, cyclosporine)
• Novel agents in development: parsaclisib, ibrutinib, rilzabrutinib, zanubrutinib, obexelimab, ianalumab, povetacicept (B-cell targets); bortezomib, daratumumab (plasma cells); fostamatinib, sovleplenib (spleen tyrosine kinase); nipocalimab (neonatal Fc receptor)

Cold Agglutinin Disease (CAD) - 20-25% of Cases

Critical Distinction

CAD does NOT respond to steroids, splenectomy, or most immunosuppressants that work for wAIHA 6. This fundamental difference mandates accurate antibody identification before treatment.

First-Line Treatment

Rituximab with or without bendamustine 2, 3:

• This is the primary treatment for CAD requiring therapy
• Targets the underlying B-cell clone producing cold agglutinins

Emerging Options

Complement inhibition with sutimlimab is a new therapeutic option specifically for CAD 3:

• Anti-C1s drugs improve anemia
• Important caveat: These do not treat peripheral circulatory failure from erythrocyte aggregation 8
• B-cell-targeted therapies remain necessary for patients with severe circulatory symptoms

Special Situation: Delayed Hemolytic Transfusion Reaction (DHTR) with Hyperhemolysis in Sickle Cell Disease

This represents a distinct, life-threatening scenario requiring specific management 7:

Definition and Recognition

• Hemoglobin drops below pretransfusion levels within 21 days post-transfusion
• May occur with negative DAT and no identifiable antibody
• Avoid additional transfusions if possible, as hemolysis may worsen and cause multiorgan failure

Treatment Protocol

Initiate immunosuppressive therapy promptly for life-threatening hemolysis 7:

First-line agents 7:

• IVIg: 0.4-1 g/kg/day for 3-5 days (up to total 2 g/kg)
• High-dose steroids: Methylprednisolone or prednisone 1-4 mg/kg/day

Second-line agent 7:

• Eculizumab: 900-1200 mg weekly for adults >40 kg
• Requires immediate vaccination (MenACWY, MenB) and ciprofloxacin prophylaxis for meningococcal infection risk

Rituximab indication 7:

• Dose: 375 mg/m² repeated after 2 weeks
• Primarily for preventing additional alloantibody formation in patients requiring further transfusion

Transfusion Strategy

If life-threatening anemia necessitates transfusion despite ongoing hemolysis, use extended antigen-matched red cells (C/c, E/e, K, Jka/Jkb, Fya/Fyb, S/s) 7.

Supportive Care

Initiate in all patients 7:

• Erythropoietin with or without IV iron
• Serial monitoring: hemoglobin, hematocrit, HbA/HbS fractions, reticulocyte count, bilirubin, LDH, urinalysis for hemoglobinuria

Common Pitfalls to Avoid

1. Do not treat CAD with steroids or splenectomy - these are ineffective and delay appropriate therapy 6
2. Do not continue transfusions in hyperhemolysis unless absolutely life-threatening, as this worsens hemolysis 7
3. Do not assume all hemolytic anemia is autoimmune - DAT-negative cases require different diagnostic workup 4
4. Do not use rituximab as monotherapy for DHTR - it prevents future antibodies but doesn't stop acute hemolysis 7
5. Do not delay immunosuppression in severe wAIHA - add rituximab early rather than waiting for steroid failure 1

Drug-Induced and Checkpoint Inhibitor-Related AIHA

For immune checkpoint inhibitor-related hemolytic anemia (irAIHA) 5:

• Grade 1-2: Supportive care only
• Grade 3-4: Methylprednisolone for 2-4 weeks with slow taper
• Steroid-refractory cases: Add cyclosporine or other immunosuppressants
• Grade 4 or recurring grade 3: Permanently discontinue immunotherapy